Chelsea Therapeutics to cut jobs, CEO resigns
July 10 (Reuters) - Chelsea Therapeutics International Ltd said it plans to "significantly reduce" its workforce and explore strategic options, barely a week after the U.S. health regulator asked for an additional trial to approve its hypotension drug Northera.
The company also said Chief Executive Simon Pedder will step down effective immediately.
The job cut is expected to be completed in the third quarter of 2012 and will result in annual salary reductions of at least $3.5 million, excluding any one-time restructuring charges.
- Flights delayed as air pollution hits record in Shanghai
- White House reverses, says Obama met uncle and lived with him during law school
- South Africa mourns Mandela, will bury him on December 15 |
- French launch Central African Republic mission but deaths mount
- Supreme Court to decide on patent protections for software